We recently showed that phosphoinositide-3-kinase-␥-deficient (PI3K␥ Ϫ/Ϫ ) mice have enhanced cardiac contractility attributable to cAMP-dependent increases in sarcoplasmic reticulum (SR) Ca 2ϩ content and release but not L-type Ca 2ϩ current (I Ca,L ), demonstrating PI3K␥ locally regulates cAMP levels in cardiomyocytes. Because phosphodiesterases (PDEs) can contribute to cAMP compartmentation, we examined whether the PDE activity was altered by PI3K␥ ablation. Selective inhibition of PDE3 or PDE4 in wild-type (WT) cardiomyocytes elevated Ca 2ϩ transients, SR Ca 2ϩ content, and phospholamban phosphorylation (PLN-PO 4 ) by similar amounts to levels observed in untreated PI3K␥ Ϫ/Ϫ myocytes. Combined PDE3 and PDE4 inhibition caused no further increases in SR function. By contrast, only PDE3 inhibition affected Ca 2ϩ transients, SR Ca 2ϩ loads, and PLN-PO 4 levels in PI3K␥ Ϫ/Ϫ myocytes. On the other hand, inhibition of PDE3 or PDE4 alone did not affect I Ca,L in either PI3K␥ Ϫ/Ϫ or WT cardiomyocytes, whereas simultaneous PDE3 and PDE4 inhibition elevated I Ca,L in both groups. Ryanodine receptor (RyR 2 ) phosphorylation levels were not different in basal conditions between PI3K␥ Ϫ/Ϫ and WT myocytes and increased in both groups with PDE inhibition. Our results establish that L-type Ca 2ϩ channels, RyR 2 , and SR Ca 2ϩ pumps are regulated differently in distinct subcellular compartments by PDE3 and PDE4. In addition, the loss of PI3K␥ selectively abolishes PDE4 activity, not PDE3, in subcellular compartments containing the SR Ca 2ϩ -ATPase but not RyR 2 or L-type Ca 2ϩ channels. (Circ Res. 2007;101:400-408.)
P hosphoinositide 3-kinases (PI3Ks) are a family of enzymes that have the unique capacity to function as both lipid and protein kinases. PI3Ks have been divided into 3 classes (I, II, and III) based on their substrate specificity, mode of activation, and molecular structure. 1 PI3K␣ and PI3K␥, which are members of PI3K subclass IA and IB, respectively, are the two main isoforms expressed in cardiomyocytes. 1 Whereas PI3K␣ regulates heart growth, 2 PI3K␥ has emerged as an important regulator of cardiac contractility and cardiac excitation-contraction coupling (ECC) [3] [4] [5] [6] [7] by regulating basal cAMP levels [3] [4] [5] 8 and phospholamban (PLN) phosphorylation. 3, 5 We recently established that cardiomyocytes lacking PI3K␥ have cAMP-dependent increases in sarcoplasmic reticulum (SR) Ca 2ϩ load and release without changes in L-type Ca 2ϩ current (I Ca,L ), 7, 9 which is a prototype for regulation by cAMP-dependent protein kinase A (PKA) (see review 8 ). Although the basis for the cAMP compartmentation in PI3K␥-deficient mice is unclear, phosphodiesterases (PDEs) are a family of enzymes that are critical components of macromolecular complexes involved in the subcellular compartmentation of cAMP-PKA signaling 8,10 -12 by locally hydrolyzing cAMP or cGMP. 13, 14 For instance, cardiacspecific overexpression of human adenylate cyclase type 8 (AC8) in mice enhances cAMP levels, contractility, and Ca 2ϩ transient, without affecting I Ca,L 15 because of PDE-based compartmentation of cAMP hydrolysis. 10 Although the dominant PDEs regulating cAMP-PKA in heart are PDE3A and several members of the PDE4 family, 16, 17 a recent study reported that PDE3B activity is eliminated in PI3K␥ Ϫ/Ϫdeficient hearts 5, 6 and that PI3K␥ stimulates PDE3B, 5, 18 even though PDE3B is primarily expressed in vascular smooth muscle cells and not in cardiomyocytes. 13, 19 The aim of this study was to elucidate the involvement of PDEs in the regulation of L-type Ca 2ϩ channels and SR Ca 2ϩ handling by PI3K␥. Our results demonstrate that both PDE3 and PDE4 activities are required in mouse myocardium to maintain cAMP-PKA signaling at baseline levels within microdomains containing SR Ca 2ϩ pumps and RyR 2 , but not in microdomains surrounding L-type Ca 2ϩ channels. In addition, the loss of PI3K␥ abolishes PDE4, but not PDE3B, activity in microdomains containing SR Ca 2ϩ pumps.
Materials and Methods

Mouse Usage and Cardiomyocytes Isolation
The generation of WT and PI3K␥ Ϫ/Ϫ mice has previously been described 20 (see supplemental materials, available online at http://circres.ahajournals.org).
Electrophysiology and SR Ca 2؉ Content
I Ca,L was measured at room temperature (22°C, 1 mL min Ϫ1 ) with whole-cell patch-clamp technique 21 under voltage-clamp mode, whereas the SR Ca 2ϩ content was estimated by integrating the Na ϩ -Ca 2ϩ exchanger current (I NCX ) induced by brief (10 sec) applications of 20 mmol/L caffeine, as previously described 7 (see supplemental materials).
Fluorescence
Voltage-clamped myocytes were loaded via the patch-pipette with fluo-3, 5K ϩ salt to record Ca 2ϩ transients simultaneously to I Ca,L , as previously described 7 (see supplemental materials).
Western Blots
The phosphorylation levels of PLN and cardiac RyR 2 were measured as previously described. 3, 22 We measured RyR 2 phosphorylation at position S2030 because, unlike S2808, S2030 shows very low baseline phosphorylation. 22 (see supplemental materials).
Statistics
Statistical significance was assessed using a 1-way analysis of variance (ANOVA) followed by either a Student Neuman-Keuls test or a Kruskal-Wallis test when the data were nonparametric. Paired t tests were used when comparing results from the same cardiomyocyte. PϽ0.05 was considered statistically significant. Data are presented as meanϮSEM.
Results
Because PDEs are critical determinants of subcellular cAMP-PKA compartmentation, 10 -12 we examined whether the major PDEs isoforms regulating cAMP in myocardium (ie, PDE3 and PDE4) 24, 25 mediate the effects of PI3K␥ on cAMP compartmentation in vicinity of the SR. Figure 1 shows that perfusion of myocytes with milrinone for 8 minutes, at doses capable of selectively inhibiting PDE3, 13, 26 increased amplitudes and accelerated decay rates (Table) of Ca 2ϩ transients in both WT and PI3K␥ Ϫ/Ϫ myocytes, establishing that PDE3 is active in PI3K␥ Ϫ/Ϫ . To confirm that the effects of milrinone were selective, 26 the PDE3 inhibitor, cilostazol, at doses that selectively inhibit PDE3, 26 yielded identical results to milrinone (supplemental Table I ). Furthermore, 1 mol/L milrinone had no effect, whereas the effects of 100 mol/L milrinone were indistinguishable from 10 mol/L milrinone (supplemental Table I ).
In contrast, rolipram application, at doses that selectively inhibit PDE4, 13 had no effect on Ca 2ϩ transients in PI3K␥ Ϫ/Ϫ 
Kerfant et al PI3K␥, PDE3, and PDE4 in Cardiomyocytes
myocytes, while enhancing the amplitude and decay rates of fluo-3 fluorescence in WT myocytes to levels indistinguishable from untreated PI3K␥ Ϫ/Ϫ myocytes ( Figure 2 and Table) . These findings suggest that PDE4 activity is lost in PI3K␥ Ϫ/Ϫ myocytes. As expected from pharmacological studies, 19 1 mol/L rolipram had no effect (supplemental Table I Time to peak for Ca 2ϩ transient was measured as time from depolarization to the peak of fluorescence; 50% decay was determined by fitting Ca 2ϩ transient decay with a monoexponential function; fast and slow were determined by fitting I Ca,L decay with a biexponential function; Controls were added (nϭ25) because there was no difference in control values between each group. Only 1 condition was tested for each cell. *PϽ0.01 (same groups), †PϽ0.01 (between KO and WT) . Rol indicates rolipram; Mil, milrinone. PDE3 and PDE4 inhibition cannot underlie the increased amplitudes or accelerated kinetics of the F/F 0 ratios observed (see supplemental materials).
To assess the effects of PDEs inhibition on I Ca,L , we measured I Ca,L both at 8 minutes after membrane rupture in the absence of drug and again after 8 minutes of drug application (ie, 16 minutes after membrane rupture). PDE3 inhibition did not affect (PϾ0.5) I Ca,L amplitudes ( Figure 1B ) and did not change either the maximum conductance of I Ca,L (ie, G max ) in WT myocytes (112Ϯ14 pS/pF control versus 98Ϯ10 pS/pF milrinone, nϭ7) and PI3K␥ Ϫ/Ϫ myocytes (117Ϯ5 pS/pF control versus 111Ϯ9 pS/pF milrinone, nϭ8) or voltage for half-maximal activation (V 1/2 ) of I Ca,L (supplemental Table I ). Milrinone did, however, accelerate the Ca 2ϩ -dependent phase of I Ca,L inactivation (ie, fast ) in both groups (Table) , consistent with increased Ca 2ϩ transients 7, 8 (see below). The absence of I Ca,L changes were not caused by rundown because no differences in I Ca,L were observed when comparisons were made between treated and untreated myocytes 16 minutes after membrane rupture (supplemental Figure I) .
PDE4 inhibition also did not affect I Ca,L ( Figure 2B ). Indeed, rolipram did not change (PϾ0.5) either G max of I Ca,L in WT myocytes (107Ϯ4 pS/pF control versus 94Ϯ6 pS/pF rolipram, nϭ6) and PI3K␥ Ϫ/Ϫ (115Ϯ9 pS/pF control versus 101Ϯ11 pS/pF rolipram, nϭ8) myocytes or V 1/2 of I Ca,L (Table  S1 ). Rolipram did, however, abbreviate fast in WT myocytes, but not in PI3K␥ Ϫ/Ϫ myocytes (Table) , because of secondary effects on Ca 2ϩ transients (See below). Again, no differences in I Ca,L amplitudes were observed 16 minutes after membrane rupture between myocytes treated with PDE4 inhibitors and untreated myocytes (supplemental Figure I) .
Because SR Ca 2ϩ release strongly affects I Ca,L via Ca 2ϩmediated inactivation, the effects of PDEs inhibition could be partially masked by simultaneous changes in Ca 2ϩ transients. Indeed, the fast component of the inactivation rate of I Ca,L (ie, fast ), which reflects Ca 2ϩ -mediated inactivation, correlated strongly with Ca 2ϩ transient amplitudes (Table) . Thus, I Ca,L measurements were repeated in myocytes dialyzed with 4 mmol/L EGTA to suppress SR Ca 2ϩ release. 27 Although EGTA does not eliminate Ca 2ϩ -mediated inactivation, 28 it did abolish differences in fast as expected. 27 With EGTA in the pipette, PDE3 or PDE4 inhibition alone did not affect I Ca,L amplitudes or G max in either WT or PI3K␥ Ϫ/Ϫ myocytes (data not shown).
The results above suggest that PDEs regulate baseline cAMP levels in subcellular compartments containing the SR, but not L-type Ca 2ϩ channels, and that PI3K␥ is required for PDE4 activity in the SR compartment. To more directly investigate SR function, SR Ca 2ϩ content was measured in myocytes dialyzed with clamped free Ca 2ϩ concentrations (Ϸ75 nmol/L). After 8 minutes of dialysis, caffeine (20 mmol/L) was applied to induce SR Ca 2ϩ release, allowing SR Ca 2ϩ content to be measured by integrating the forwardmode NCX current (͐I NCX ). 29 Figure 3 shows that, without PDEs inhibitors, the ͐I NCX was higher (PϽ0.05) in PI3K␥ Ϫ/Ϫ compared with WT myocytes. Milrinone increased ͐I NCX in both groups, whereas PDE4 inhibition only increased ͐I NCX in WT myocytes. Decay times for caffeine-induced I NCX were not different between the groups (data not shown), suggesting that I NCX densities were not detectably altered by PI3K␥ ablation.
Consistent with the observed differences in SR Ca 2ϩ content, the PLN-PO 4 /PLN ratio was elevated in PI3K␥ Ϫ/Ϫ compared with WT myocytes (Figure 3C and 3D) . PDE3 inhibition increased PLN-PO 4 /PLN in both groups, whereas PDE4 inhibition enhanced this ratio in WT myocytes only. Although alterations in PLN-PO 4 can explain the functional differences between the various groups, RyR 2 phosphorylation could also contribute to enhanced SR Ca 2ϩ release. 30 Under basal conditions, RyR 2 -PO 4 levels at position S2030, expressed as a fraction of the maximal phosphorylation achieved with isoproterenol treatment, did not differ (Pϭ0.6) (Figure 4 ). On the other hand, PDE3 or PDE4 inhibition alone increased (PϽ0.05) RyR 2 -PO 4 levels about 2 to 3 times in both groups, revealing that the loss of PI3K␥ does not abolish PDE4 activity in junctional SR microdomains containing RyR 2 , unlike SERCA2a-containing compartments.
Because cAMP inhibitors reduce Ca 2ϩ transients and SR Ca 2ϩ content in PI3K␥ Ϫ/Ϫ myocytes, 7,8 but not WT, our findings support a model ( Figure 6A) where both PDE3 and PDE4 activities are required to maintain cAMP at basal levels in a common microdomains containing SERCA2a-PLN, with PI3K␥ being necessary for PDE4 activity. This model predicts that Ca 2ϩ transients in WT and PI3K␥ Ϫ/Ϫ myocytes should be indistinguishable when PDE3 and PDE4 are inhibited simultaneously. However, Figure 5A shows that Ca 2ϩ transients in WT myocytes treated with combined PDE3 and PDE4 inhibitors were not different from those with PDE3 or PDE4 inhibition. Moreover, with combined PDE3 and PDE4 inhibition, Ca 2ϩ transients in WT myocytes were below those observed in PI3K␥ Ϫ/Ϫ myocytes. On the other hand, Ca 2ϩ transients in PI3K␥ Ϫ/Ϫ myocytes with combined PDE3 and PDE4 inhibition were the same as those with PDE3 inhibition alone. These observations could be explained if other PI3K␥-regulated PDEs also influence cAMP levels in the SR subdomain. However, Ca 2ϩ transients with global inhibition of PDEs using IBMX (50 mol/L) were identical to those observed when PDE3 and PDE4 were inhibited simultaneously (Table) . Taken together, these results suggest that multiple microdomains with distinct cAMP regulation exist in the SR subcellular compartment (see Discussion).
When Ca 2ϩ transients were present, combined inhibition of PDE3 and PDE4 did not increase (Pϭ0.6) G max for I Ca,L in WT myocytes but increased G max (PϽ0.05) in PI3K␥ Ϫ/Ϫ ( Figure  5A ). With EGTA in the pipette, combined PDE3 and PDE4 inhibition increased (PϽ0.001) G max by 63Ϯ9% and shifted (PϽ0.001) V 1/2 from Ϫ12.5Ϯ0.8 mV toϪ20.7Ϯ0.9 mV in PI3K␥ Ϫ/Ϫ , while increasing (PϽ0.05) G max by only 15Ϯ10% and modestly shifting (PϽ0.05) V 1/2 fromϪ11.4Ϯ0.8 mV to Ϫ17.6Ϯ2.0 mV in WT myocytes. The larger increases in I Ca,L observed when EGTA was included in the pipette ( Figure 5B ) may be related to reductions in either Ca 2ϩ -dependent inhibition of AC isoforms 31 or Ca 2ϩ -mediated I Ca,L inactivation, as discussed below.
Discussion
Previously we established that elevated cardiac contractility in PI3K␥ Ϫ/Ϫ mice results from increased SR Ca 2ϩ cycling without changes in I Ca,L . 3, 7, 8 In this study we found that both PDE3 and PDE4 activities are required in mouse myocardium to maintain cAMP-PKA signaling at baseline levels within microdomains containing SR Ca 2ϩ pumps and RyR 2 , but not in microdomains surrounding L-type Ca 2ϩ channels. In addition, the loss of PI3K␥ abolishes PDE4 activity in microdomains containing SR Ca 2ϩ pumps.
The increased SR Ca 2ϩ content as well as elevated Ca 2ϩ transient amplitudes and relaxation rates observed with either PDE3 and PDE4 inhibition in WT myocytes are consistent with previous studies. 13, 19, 26, [32] [33] [34] [35] The Ca 2ϩ changes with PDE inhibition appeared to result from local cAMP elevations because they were tightly linked to increased PLN-PO 4 /PLN ratios without alterations in I Ca,L . It is conceivable that increased RyR 2 -PO 4 levels also contribute to the changes in Ca 2ϩ homeostasis observed with PDE inhibition because RyR 2 phosphorylation enhances SR Ca 2ϩ leak 12 and release. 30 However, RyR 2 phosphorylation is predicted to decrease SR Ca 2ϩ loads and to have little effect on Ca 2ϩ transient relaxation, contrary to our observations. Importantly, because PDE4 and PDE3 inhibition alone had similar effects on Ca 2ϩ cycling and because cAMP antagonists don't affect Ca 2ϩ cycling in mouse myocytes at baseline, 7, 8 our results establish that PDE3 and PDE4 enzymes are equally important in maintaining the cAMP at basal levels in microdomains containing SERCA2a-PLN. This conclusion is consistent with the high expression levels of PDE3A and PDE4D we observed in mouse cardiomyocytes, as reported previous- ly 13, 19 as well as with the ability of PDE4D to coimmunoprecipitate with SERCA2a (supplemental Figure II) . Moreover, PDE3A can be isolated from cardiac SR microsomal fractions, 36, 37 and PDE3 inhibition increases SERCA2a activity 36, 37 in cardiomyocytes.
A rather unexpected finding in our studies was the inability of combined PDE3 and PDE4 to alter Ca 2ϩ transients beyond that observed with PDE3 or PDE4 inhibition alone. These observations could be explained by several mechanisms that are not mutually exclusive. For example, other PDEs isoforms could assist in the locally controlling cAMP hydrolysis. But this seems unlikely, because global PDE inhibition with IBMX produced effects identical to those observed with combined PDE3-PDE4 inhibition. Alternatively, it is also conceivable that the interactions between the PDEs are complicated via feedback regulation involving increased PDE3 and PDE4 activities by PKA-dependent phosphorylation. 13, 19, 23, 38 However, this type of interaction should enhance, not reduce, the effects of combined or global inhibition of PDEs. A more plausible explanation would be that, under basal conditions, more than 1 local pool of cAMP exists in microdomains containing target SERCA2a-PLN effectors. The precise characteristics of cAMP regulation in these pools are undoubtedly complex depending on the distribution and enzyme kinetics of PDE3 and PDE4 as well as the local cAMP production, 39 which is also highly compartmentalized. 40 For example, the EC50 for cAMP hydrolysis by PDE3 (ie, 0.1 to 0.5 mol/L) is Ϸ10-fold higher than for PDE4 (0.5 to 4 mol/L), 13, 19 thereby allowing PDE3 to dominate cAMP hydrolysis at low cAMP concentrations compared with PDE4. Clearly, further studies will be needed to fully identify the molecular and structural basis for the subcellular regulation of SR function by PDE3 and PDE4.
Our results demonstrate that Ca 2ϩ transients, SR Ca 2ϩ content, and PLN-PO 4 levels were identical between PI3K␥ Ϫ/Ϫ myocytes under basal conditions and WT myocytes after PDE4 inhibition, and were unaffected in PI3K␥ Ϫ/Ϫ myocytes by PDE4 inhibition either under baseline conditions or when PDE3 was inhibited. These observations reveal that PDE4 activity is absent in the SR subdomains containing SERCA2a-PLN of PI3K␥ Ϫ/Ϫ myocytes. These results are surprising because previous studies concluded that the loss of PI3K␥ protein, but not of its enzymatic activity, abolishes PDE3B activity in the myocardium. 5 However, we were unable to detect PDE3B expression in mouse cardiomyocytes (supplemental Figure II) , consistent with previous reports, 13, 19 and a recent study found that PI3K␥ binding does not activate PDE3B. 18 Furthermore, ablation of the lipid phosphatase PTEN increases cardiac PIP 3 and impairs cardiac contractility 3 and these effects of PTEN disruption were abolished by PI3K␥ deletion, 3 suggesting that PIP 3 generation by PI3K␥ is an important factor in the regulation of cardiac contractility.
Interestingly, Ca 2ϩ transients, SR Ca 2ϩ loads, and PLN-PO 4 were greater in PI3K␥ Ϫ/Ϫ myocytes after PDE3 inhibition than in WT myocytes with combined PDE3-PDE4 inhibition. Given the inability of combined PDE3-PDE4 inhibition in WT cardiomyocytes to alter Ca 2ϩ cycling and PLN-PO 4 levels beyond that observed with PDE3 or PDE4 inhibition alone, one would anticipate that PDE3 inhibition in PI3K␥ Ϫ/Ϫ myocytes would have minimal impact. These unanticipated findings could arise if PDE4 activity was not completely inhibited in WT myocytes by 10 mol/L rolipram. 41 However, 10-fold higher doses of rolipram, which fully inhibit PDE4, 41 had no further effect on Ca 2ϩ transient in WT myocytes. Alternatively as discussed above, these results could reflect the presence of multiple cAMP pools with complex distribution patterns of PDEs and cAMP production. In fact, our results in WT and PI3K␥ Ϫ/Ϫ mice support a model wherein there are two pools of cAMP in SR microdomains containing SERCA2a/PLN ( Figure 6 ). In one pool, both PDE3 and PDE4 activities are required to maintain cAMP levels at basal levels. In the second pool, PDE3 activity is necessary to stave off elevations in cAMP arising from increased local cAMP production, as shown previously in PI3K␥-deficient myocardium as a consequence of reduced local G␣-i activity 6 and increased AC activity.
Although no differences in I Ca,L amplitudes were observed between PI3K␥ Ϫ/Ϫ and WT myocytes, the inactivation rates of I Ca,L . 7, 8 were accelerated in PI3K␥ Ϫ/Ϫ myocytes, which can be attributed to increased Ca 2ϩ -mediated inactivation secondary to elevated Ca 2ϩ transients. 42 To eliminate the complicating effects of Ca 2ϩ transients on I Ca,L , we dialyzed myocytes with high levels of EGTA. Although EGTA does not eliminate Ca 2ϩ -mediated inactivation, 28 it successfully eliminated the effects of SR Ca 2ϩ release on I Ca,L in our studies. When WT myocytes were dialyzed with EGTA, PDE3 or PDE4 inhibition alone did not affect I Ca,L whereas combined PDE3-PDE4 inhibition induced modest I Ca,L increases (Ϸ15% at Ϫ10mV), as reported previously. 16, 17 Combined PDE3-PDE4 inhibition in WT myocytes shifted V 1/2 to negative voltages without affecting the G max , verifying that V 1/2 and G max for I Ca,L can be separately regulated. 43 Thus, in microdomains containing L-type Ca 2ϩ channels, either PDE3 or PDE4 activity alone is sufficient to maintain cAMP at basal levels. Several explanations could account for these observations. For example, because basal I Ca,L is unchanged by cAMP antagonists, 7,8 the inability of PDE3 or PDE4 inhibition alone to alter I Ca,L could arise because of low basal cAMP production in I Ca,L microdomains or because high cAMP levels are required to enhance I Ca,L , or both. In this respect, it is conceivable that cAMP levels were in fact elevated in I Ca,L microdomains but did not rise to levels required to modulate I Ca,L . Alternatively, the I Ca,L microdomains could possess high activity of other PDEs isoforms, although this seems unlikely because IBMX enhanced I Ca,L by similar amounts as combined PDE4 and PDE3 inhibition in WT myocytes (data not shown).
The pattern of I Ca,L regulation in PI3K␥ Ϫ/Ϫ myocytes was similar to WT myocytes, confirming that cAMP is regulated in I Ca,L microdomains by both PDE3 and PDE4. Interestingly, because PDE3 inhibition alone did not increase I Ca,L , we conclude that PDE4 activity is not abolished by PI3K␥ ablation in I Ca,L microdomains, unlike subcompartments containing SERCA2a. The molecular basis for these differences between the SERCA2a and I Ca,L subdomains is unclear, but we have found in preliminary studies that neither PDE3B nor PDE4D coimmunoprecipitate with the ␣1C subunit of the L-type Ca 2ϩ channel. Moreover, combined PDE3-PDE4 inhibition increased I Ca,L in PI3K␥ Ϫ/Ϫ far more (Ϸ2-fold) than in WT myocytes, suggesting that, as in microdomains containing SERCA2a, microdomains containing I Ca,L in PI3K␥ Ϫ/Ϫ myocytes have higher cAMP levels, possibly resulting from decreased G␣-i mediated inhibition of AC activity. 6 Alternatively, PDE3 and PDE4 families have multiple subisoforms which can be localized differentially in cardiomyocytes. 17 Unfortunately, no pharmacological tools exist currently to dissect contributions of separate members of the PDE3 or PDE4 families. The molecular and anatomical basis for PDEs regulation of I Ca,L will clearly require further studies.
Another important target of cAMP-dependent PKA phosphorylation is RyR 2 , 22 which can be phosphorylated at positions S2808 and S2030. 22 Previous results have established that, unlike S2808, S2030 shows very low baseline phosphorylation levels 22 and is phosphorylated by PKA, not CaMKinase. Therefore, we assessed the RyR 2 phosphorylation status at position S2030. As with PLN-PO 4 and Ca 2ϩ homeostasis, PDE3 and PDE4 are both required to maintain basal RyR 2 -PO 4 levels in WT myocytes. These findings are not unexpected given the colocalization of these proteins in the SR, particularly the junctional SR. 30 However, unlike SERCA2a-PLN and Ca 2ϩ homeostasis, PDE4 activity in subcellular compartments containing the RyR 2 does not require PI3K␥, establishing that PI3K␥'s involvement in the PDE4dependent regulation of the SR function is unique to SERCA2a-PLN. This seems somewhat surprising because PDE4D coassembles with both SERCA2a and RyR 2 , 12 and it will be interesting to determine whether PI3K␥ is in the macromolecular complex of signaling molecules that associates with RyR 2 . 30 Our results have several important clinical implications. For example, a prominent feature of diseased myocardium is reduced Ca 2ϩ transients resulting from decreased SR Ca 2ϩ uptake, without changes in I Ca,L density. 44 -46 This pattern is the opposite to that seen in PI3K␥ Ϫ/Ϫ mice suggesting that increased PI3K␥ activity may contribute to impaired contractility in heart disease 3,4,47-50 by stimulating PDE4 activity and reducing Ca 2ϩ uptake in the SR. This suggestion is consistent with the elevated PI3K␥ activity and expression, 5, 47 as well as increased PDE4 activity, observed in heart disease. 51 These effects are expected to accentuate the impaired Ca 2ϩ handling and contractility in heart disease 46 originating from ␤-adrenergic receptor downregulation, enhanced G␣-i activity, and reduced SERCA2a expression. Clearly, future studies will be required to fully assess the contribution of PI3K␥mediated changes in local cAMP to the pathogenesis of heart disease.
